Keywords: wyeth/progenics, initiate, ph, iii, trial, poi, treatment

Wyeth/Progenics initiate Ph III trial of POI treatment

Article | 22 December 2006

Print This

Drug major Wyeth and fellow USA-based Progenics Pharmaceuticals have initiated the second of two global, pivotal Phase III clinical trials ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in